ArticleInvestigational new drugs2023

A dose escalation/expansion study evaluating dose, safety, and efficacy of the novel tyrosine kinase inhibitor surufatinib, which inhibits VEGFR 1, 2, & 3, FGFR 1, and CSF1R, in US patients with neuroendocrine tumors.

Arvind Dasari et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.